As of 2025-09-16, the Intrinsic Value of Summit Therapeutics Inc (SMMT) is -0.95 USD. This SMMT valuation is based on the model Peter Lynch Fair Value. With the current market price of 18.94 USD, the upside of Summit Therapeutics Inc is -105.03%.
Based on its market price of 18.94 USD and our intrinsic valuation, Summit Therapeutics Inc (SMMT) is overvalued by 105.03%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.95 - -0.95 | -0.95 | -105.03% |
| P/E | (1.29) - (2.15) | (1.63) | -108.6% |
| DDM - Stable | (1.04) - (3.71) | (2.37) | -112.5% |
| DDM - Multi | (0.02) - (0.06) | (0.03) | -100.2% |
| Market Cap (mil) | 17,679.81 |
| Beta | 3.61 |
| Outstanding shares (mil) | 933.46 |
| Enterprise Value (mil) | 17,381.94 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.72% |
| Cost of Debt | 5.00% |
| WACC | 8.19% |